Nimitha R Mathew,Francis Baumgartner,Lukas Braun,David O'Sullivan,Simone Thomas,Miguel Waterhouse,Tony A Müller,Kathrin Hanke,Sanaz Taromi,Petya Apostolova,Anna L Illert,Wolfgang Melchinger,Sandra Duquesne,Annette Schmitt-Graeff,Lena Osswald,Kai-Li Yan,Arnim Weber,Sonia Tugues,Sabine Spath,Dietmar Pfeifer,Marie Follo,Rainer Claus,Michael Lübbert,Christoph Rummelt,Hartmut Bertz,Ralph Wäsch,Johanna Haag,Andrea Schmidts,Michael Schultheiss,Dominik Bettinger,Robert Thimme,Evelyn Ullrich,Yakup Tanriver,Giang Lam Vuong,Renate Arnold,Philipp Hemmati,Dominik Wolf,Markus Ditschkowski,Cordula Jilg,Konrad Wilhelm,Christian Leiber,Sabine Gerull,Jörg Halter,Claudia Lengerke,Thomas Pabst,Thomas Schroeder,Guido Kobbe,Wolf Rösler,Soroush Doostkam,Stephan Meckel,Kathleen Stabla,Stephan K Metzelder,Sebastian Halbach,Tilman Brummer,Zehan Hu,Joern Dengjel,Björn Hackanson,Christoph Schmid,Udo Holtick,Christof Scheid,Alexandros Spyridonidis,Friedrich Stölzel,Rainer Ordemann,Lutz P Müller,Flore Sicre-de-Fontbrune,Gabriele Ihorst,Jürgen Kuball,Jan E Ehlert,Daniel Feger,Eva-Maria Wagner,Jean-Yves Cahn,Jacqueline Schnell,Florian Kuchenbauer,Donald Bunjes,Ronjon Chakraverty,Simon Richardson,Saar Gill,Nicolaus Kröger,Francis Ayuk,Luca Vago,Fabio Ciceri,Antonia M Müller,Takeshi Kondo,Takanori Teshima,Susan Klaeger,Bernhard Kuster,Dennis (Dong Hwan) Kim,Daniel Weisdorf,Walter van der Velden,Daniela Dörfel,Wolfgang Bethge,Inken Hilgendorf,Andreas Hochhaus,Geoffroy Andrieux,Melanie Börries,Hauke Busch,John Magenau,Pavan Reddy,Myriam Labopin,Joseph H Antin,Andrea S Henden,Geoffrey R Hill,Glen A Kennedy,Merav Bar,Anita Sarma,Donal McLornan,Ghulam Mufti,Betul Oran,Katayoun Rezvani,Omid Shah,Robert S Negrin,Arnon Nagler,Marco Prinz,Andreas Burchert,Andreas Neubauer,Dietrich Beelen,Andreas Mackensen,Nikolas von Bubnoff,Wolfgang Herr,Burkhard Becher,Gerard Socié,Michael A Caligiuri,Eliana Ruggiero,Chiara Bonini,Georg Häcker,Justus Duyster,Jürgen Finke,Erika Pearce,Bruce R Blazar,Robert Zeiser,Dennis Kim

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F -induced myeloproliferative neoplasms

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.

Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling: Erratum